Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)
India flag India · Delayed Price · Currency is INR
1,566.00
-45.30 (-2.81%)
Last updated: Nov 16, 2026, 3:29 PM IST

Symbiotec Pharmalab Revenue

Symbiotec Pharmalab had revenue of 2.80B INR in the quarter ending September 30, 2026. This brings the company's total for the last twelve months to 9.69B. In the fiscal year ending March 31, 2026, Symbiotec Pharmalab had annual revenue of 8.69B with 15.65% growth. That makes Symbiotec Pharmalab the 22,511th largest company in the world by revenue and 1,361st in India.

Revenue (ttm)
9.69B
Revenue Growth
+15.65%
P/S Ratio
10.39
Revenue / Employee
5.06M
Employees
1,915
Market Cap
100.63B

Revenue Chart

Revenue by Geography

  • India 2.87B 33.0%
  • Europe 2.53B 29.1%
  • Rest of World 2.16B 24.8%
  • United States 1.14B 13.1%
Fiscal year ended Mar 31, 2026 See the full Symbiotec Pharmalab breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Mar 31, 20268.69B1.18B15.65%
Mar 31, 20257.52B353.07M4.93%
Mar 31, 20247.16B1.50B26.43%
Mar 31, 20235.67B-1.15B-16.91%
Mar 31, 20226.82B--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.